ArticleClinical proteomics2026
Inverse co-variation of circulating PIWIL2 and PIWIL4 in gastric adenocarcinoma: an exploratory ELISA-based study.
Article in Clinical proteomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundGastric cancer is characterized by substantial molecular heterogeneity, and RNA-mediated regulatory mechanisms may contribute to its biological complexity. PIWI-family proteins are central components of the PIWI-interacting RNA pathway, but their circulating patterns in gastric adenocarcinoma remain insufficiently characterized. This study aimed to describe circulating PIWIL1, PIWIL2, and PIWIL4 protein concentrations and explore intra-cohort co-variation patterns in patients with gastric adenocarcinoma without evaluating disease specificity, diagnostic performance, or clinical utility.
methodsIn this cross-sectional, targeted ELISA-based exploratory study, circulating PIWIL1, PIWIL2, and PIWIL4 concentrations were quantified in 93 de-identified gastric adenocarcinoma samples. PIWIL1 and PIWIL2 measurements were available for 88 samples, and PIWIL4 measurements were available for 72 samples. Commercial ELISA kits were used according to the manufacturer's instructions, but independent in-house serum validation, including dilution linearity, serum parallelism, matrix-interference testing, intra- and inter-assay precision, and orthogonal protein confirmation, was not performed. Spearman's rank correlation analysis with false discovery rate correction was used to assess exploratory intra-cohort relationships among PIWI-family proteins.
resultsPIWIL1 and PIWIL2 showed relatively stable circulating distributions, whereas PIWIL4 demonstrated pronounced heterogeneity and right-skewness. The most prominent rank-based relationship was an inverse correlation between PIWIL2 and PIWIL4 (Spearman's ρ ≈ -0.53, q < 0.001), based on 72 complete cases. This correlation remained statistically significant in sensitivity analyses using log-transformed data and exclusion of extreme values. No statistically significant correlations were observed between PIWI-family proteins and CEA or CA 19 - 9 after false discovery rate correction. Exploratory TP53 analyses were not central to the primary objective and are reported descriptively; PIWIL2 showed a modest positive correlation with TP53 (Spearman's ρ = 0.33), while PIWIL4 showed a weak positive correlation (ρ = 0.19).
conclusionsThis study identified an inverse rank-based co-variation between circulating PIWIL2 and PIWIL4 concentrations within a de-identified gastric adenocarcinoma cohort. However, this observation should be interpreted strictly as a pre-validation, exploratory ELISA-derived intra-cohort signal. Because the study lacked comparator groups, clinical annotation, tissue-level confirmation, functional assays, orthogonal protein quantification, and independent serum validation of the ELISA measurements, the observed correlation cannot be considered an analytically validated proteomic association. Further studies with confirmed assay linearity, serum parallelism, matrix-interference assessment, between-plate reproducibility, re-assay of high-value samples at appropriate dilutions, and independent analytical confirmation are required before any biological or clinical significance can be attributed to this finding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.